Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis

Autoimmunity Reviews

Volumn 10, Issue 6, 2011, Pages 331-335

  Liu, Weihong ^a,b   Peng, Bo ^a   Lu, Yumin ^b,c   Xu, Weijia ^a   Qian, Wei ^b   Zhang, Jian Ying ^b,c  

^a DALIAN MUNICIPAL CENTRAL HOSPITAL   (China)

^b UNIVERSITY OF TEXAS AT EL PASO   (United States)

^c ZHENGZHOU UNIVERSITY   (China)

Author keywords

Autoantibody; Cancer; Immunodiagnosis; P62 IMP2; P90 CIP2A; Tumor associated antigen

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; ONCOFETAL ANTIGEN; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN P62; PROTEIN P90; TUMOR ANTIGEN;

ANTIBODY DETECTION; CANCER DIAGNOSIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; NONHUMAN; PROSTATE CANCER; REVIEW; SERODIAGNOSIS;

ANIMALS; ANTIGENS, NEOPLASM; AUTOANTIBODIES; AUTOANTIGENS; HUMANS; NEOPLASMS; PROTEIN PHOSPHATASE 2; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 79953160862     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.12.002     Document Type: Review

References (45)

1. Tan E.M. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 2001, 108(10):1411-1415.
2. Old L.J., Chen Y.T. New paths in human cancer serology. J Exp Med 1998, 187(8):1163-1167.
3. Tan E.M., Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 2008, 222:328-340.
4. Anderson K.S., LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 2005, 4(4):1123-1133.
5. Imai H., Ochs R.L., Kiyosawa K., Furuta S., Nakamura R.L., Tan E.M. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Path 1992, 140(4):859-870.
6. Imai H., Nakano Y., Kiyosawa K., Tan E.M. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma. Cancer 1993, 71(1):26-35.
7. Imai H., Chan E.K.L., Kiyosawa K., Fu X., Tan E.M. Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin Invest 1993, 92(5):2419-2426.
8. Imai H., Kiyosawa K., Chan E.K.L., Tan E.M. Autoantibodies in viral hepatitis related hepatocellular carcinoma. Intervirology 1993, 35(1-4):73-85.
9. Zhang J.Y., Zhu W., Imai H., Kiyosawa K., Chan E.K.L., Tan E.M. De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin Exp Immunol 2001, 125(1):3-9.
10. Zhang J.Y., Wang X., Peng X.X., Chan E.K.L. Autoimmune responses in Chinese hepatocellular carcinoma (HCC). J Clin Immuno 2002, 22(2):98-105.
11. Zhang J.Y., Chan E.K.L., Peng X.X., Tan E.M. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med 1999, 189(7):1101-1110.
12. Mueller-Pillasch F., Lacher U., Wallrap C., Micha A., Zimmerhackl F., Hameister H., et al. Cloning of a gene highly expressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997, 14(22):2729-2733.
13. Ross A.F., Oleynikov Y., Kislauskis E.H., Taneja K.L., Singer R.H. Characterization of a Β-actin mRNA zipcode-binding protein. Mol Cell Biol 1997, 17(4):2158-2165.
14. Nielsen J., Christiansen J., Lykke-Andersen J., Johnsen A.H., Wewer U.M., Nielsen F.C. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999, 19(2):1262-1270.
15. Su T.S., Liu W.Y., Han S.H., Jansen M., Yang-Fen T.L., Peng F.K., et al. Transcripts of the insulin-like growth factors I and II in human hepatoma. Cancer Res 1989, 49(7):1773-1777.
16. Cariani E., Lasserre C., Seurin D., Hamelin B., Kemeny F., Franco D., et al. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 1988, 48(23):6844-6849.
17. Eggenshwiler J., Ludwig T., Fisher P., leighton P.A., Tilghman S.M., Efstratiadis A. Mouse mutant embryos overexpressing IGF-II exhibit phenotypic features of the Beckwith-Wiedemann and Simpson-Golabi-Behmel syndrome. Genes Devel 1997, 11(23):3128-3142.
18. Sun F.L., Dean W.L., Kelsey G., Allen N.D., Reik W. Transactivation of Igf2 in a mouse model of Beckwith-Wiedemann syndrome. Nature 1997, 389(6653):809-815.
19. Rogler C.E., Yang D., Rossetti L., Donohoe J., Alt E., Chang C.J., et al. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem 1994, 269(19):13779-13784.
20. Bates P., Fisher R., Ward A., Richardson L., Hill D.J., Graham C.F. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br J Cancer 1995, 72(5):1189-1193.
21. Schirmacher P., Held W.A., Yang D., Chisari F.V., Rustum Y., Rogler C.E. Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res 1992, 52(9):2549-2556.
22. Pasquinelli C., Bhavani K., Chisari F.V. Multiple oncogenes and tumor suppressor genes are structurally and functionally intact during hepatocarcinogenesis in hepatitis B virus transgenic mice. Cancer Res 1992, 52(10):2823-2829.
23. Lu M., Nakamura R.M., Dent E.D., Zhang J.Y., Nielsen F.C., Christiansen J., et al. Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis. Am J Pathol 2001, 159(3):945-953.
24. Doyle G.A., Betz N.A., Leeds P.F., Fleisig A.J., Prokipcak R.D., Ross J. The c-myc coding region determinant-binding protein: a member of a family of KH domain RNA-binding proteins. Nucleic Acids Res 1998, 26(22):5036-5044.
25. Leeds P., Kren B.T., Boylan J.M., Betz N.A., Steer C.J., Gruppuso P.A., et al. Developmental regulation of CRD-BP, an RNA-binding protein that stabilizes c-myc mRNA in vitro. Oncogene 1997, 14(11):1279-1286.
26. Vainer G., Vainer-Mosse E., Pikarsky A., Shenoy S.M., Oberman F., Yeffet A., et al. A role for VICKZ proteins in the progression of colorectal carcinomas: regulating lamellipodia formation. J Pathol 2008, 215(4):445-456.
27. Soo Hoo L., Zhang J.Y., Chan E.K.L. Cloning and characterization of a novel 90kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene 2002, 21(32):5006-5015.
28. Juntilla M.R., Puustinen P., Niemela M., Ahola R., Arnold H., Böttzauw T., et al. CIP2A inhibits PP2A in human malignancies. Cell 2007, 130(1):51-62.
29. Arroyo J.D., Hahn H. Involvement of PP2A in viral and cellular transformation. Oncogene 2005, 24(52):7746-7755.
30. Janssens V., Goris J., Van Hoof C. PP2A: the expected tumor suppressor. Curr Opin Genet Dev 2005, 15(1):34-41.
31. Côme C., Laine A., Chanrion M., Edgren H., Mattila E., Liu X., et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009, 15(16):5092-5100.
32. Khanna A., Böckelman C., Hemmes A., Junttila M.R., Wiksten J.P., Lundin M., et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 2009, 101(11):793-805.
33. Doyle G.A., Bourdeaux-Heller J.M., Coulthard S., Meisner L.F., Ross J. Amplification in human breast cancer of a gene encoding a c-myc mRNA binding protein. Cancer Res 2000, 60(11):2756-2759.
34. Zhang J.Y., Chan E.K.L., Peng X.X., Lu M., Wang X., Mueller F., et al. Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol 2001, 100(2):149-156.
35. Zhang J.Y., Casiano C., Peng X.X., Koziol J., Chan E.K.L., Tan E.M. Enhancement of antibody detection in cancer using a panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003, 12(2):136-143.
36. Shi F.D., Zhang J.Y., Liu D., Rearden A., Elliot M., Nachtsheim D., et al. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate 2005, 63(3):252-258.
37. Sheever M.A., Disis M.L., Bernahrd H., Grarlow J.R., Hand S.L., Huseby E.S., et al. Immunity to oncogenic proteins. Immunol Rev 1995, 145:33-59.
38. Crawford L.V., Pim D.C., Bulbrook R.D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982, 30(4):403-408.
39. Soussi T. p53 antibodies in the sera of patients with various types of cancer. A review. Cancer Res 2000, 60(7):1777-1788.
40. Disis M.L., Pupa S.M., Gralow J.R., Dittadi R., Menard S., Cheever M.A. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997, 15(11):3363-3367.
41. Keene J.D. Why is Hu where? Shuttling of early response gene messenger RNA subsets. Proc Natl Acad Sci USA 1999, 96(1):5-7.
42. Stockert E., Jager E., Chen Y.T., Scanlan M.J., Gout I., Karbach J., et al. A survey of humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998, 187(8):1349-1354.
43. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3(8):917-992.
44. Daniels T., Zhang J., Gutierrez I., Elliot M.L., Yamada B., Heeb M.J., et al. Antinuclear autoantibodies in PCa: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate 2005, 62(1):14-26.
45. Winter S.F., Minna J.D., Johnson B.E., Takahashi T., Gazdar A.F., Carbone D.P. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992, 52(15):4168-4174.